Drug Discovery Service

Drug Discovery Service

Diabetes mellitus (DM) is a metabolic disease, which arises from a complete deficiency of insulin production or inability to utilize this hormone. There are possibilities in using antibody therapy, gene therapy and stem cells as therapeutic targets for diabetes. As an experienced drug discovery company, Ace Metabolism can provide the therapy and drug discovery services related to diabetes.

Therapies of Diabetes

Diabetes mellitus is a serious and lifelong condition commonly characterized by abnormally elevated blood glucose levels due to a failure in insulin production or a decrease in insulin sensitivity and function. If left untreated, diabetes can cause many health complications. Acute complications can include diabetic ketoacidosis, hyperosmolar hyperglycemic state, or death. Besides insulin and oral hypoglycemic agents, other treatments such as gene therapy and induced β-cells regeneration can be introduced to manage diabetes.

  • Stem Cell Therapy
    Cell and gene therapy has always been thought to be able to recover eventually β-cell function, the ultimate means to cure diabetes. Stem cell therapy use islet-like insulin-producing cells which derived from human pluripotent stem cells to treat diabetes.
  • Gene Therapy
    Viral techniques such as lentivirus, adenovirus and AAV as well as non-viral techniques such as liposomes and naked DNA have been used for insulin gene delivery into different tissues, for example, pancreas, liver, adipocytes and muscle.
  • Small Molecule Drug
    Insulin injection remains the main treatment for T1DM. Exogenous insulin can be combined with various oral antidiabetic drugs to allow insulin dosage lowering for T2DM.
  • Fig 2. Small Molecule Drug

  • Antibody Therapy
    Diabetes is widely considered to be a T cell driven autoimmune disease resulting in reduced insulin production due to dysfunction/destruction of pancreatic β-cells. there continues to be a need for immunotherapies that selectively reestablish persistent β cell-specific self-tolerance for the prevention and remission of diabetes. The utilization of monoclonal antibodies (mAb) is one strategy to target specific immune cell populations inducing autoimmune-driven pathology.

mAb therapies to ameliorate type 1 diabetesmAb therapies to ameliorate type 1 diabetes (Ke, Qi et al. 2021)

Our Services

The compound has the desired activity in a compound screen and whose activity is confirmed upon retesting. Ace Metabolism can provide a complementary set of technologies to help with the drugs discovery. Our services include but not limited to the followings.

Fig 4. Stem Cell Therapy Development

Stem Cell Therapy Development

Providing service to generate islet-like cells through induced pluripotent stem cell (iPSC) technology for stem cell development.

Fig 5. Gene Therapy Development

Gene Therapy Development

Using lipid-based transfection, electroporation, viral approaches or genome engineering tools such as CRISPR or TALEN and developing gene therapy vector.

Fig 6. Antidiabetics Development

Antidiabetics Development

Developing antidiabetics (inhibitors and activators, etc.) for related targets and designing and developing drug delivery system.

Fig 7. Antibody Therapy Development

Antibody Therapy Development

Developing diabetes-related monoclonal antibody, antibody drug conjugate (ADC), bispecific antibody, allosteric antibody, etc.

Features of Our Services

Highly CustomizableHighly Customizable

One-stop ServicesOne-stop Services

High QualitysHigh Quality

Professional TeamProfessional Team

Ace Metabolism can accelerate the therapeutic development and drug discovery process about diabetes for our clients worldwide. Our assays are developed and processed with the highest standard and the results are delivered on time without compromising quality. Most of those assays are suitable for drug discovery. Please feel free to contact us.


  1. Donath, M. Y. Targeting inflammation in the treatment of type 2 diabetes: time to start. Nature Reviews Drug Discovery, 2014, 13(6), 465–476.
  2. Ke, Qi et al. "Evolving Antibody Therapies for the Treatment of Type 1 Diabetes." Frontiers in immunology vol. 11 624568. 18 Feb. 2021
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Related Services
Related Products
Contact Info
Copyright © Ace Metabolism. All Rights Reserved.